½ÃÀ庸°í¼­
»óǰÄÚµå
1788505

¼¼°èÀÇ ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ½ÃÀå : »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ ¹× ¿¹Ãø(2025-2035³â)

Nanotechnology Drug Delivery Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2035

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Transparency Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 192 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ - ºÐ¼® ¹üÀ§

TMRÀÇ Á¶»ç º¸°í¼­ "¼¼°èÀÇ ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ½ÃÀå"Àº 2025-2035³âÀÇ ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ÁöÇ¥¿¡ ´ëÇÑ ±ÍÁßÇÑ ÅëÂû·ÂÀ» ¾ò±â À§ÇØ °ú°Å¿Í ÇöÀçÀÇ ¼ºÀå µ¿Çâ°ú ±âȸ¸¦ Á¶»çÇß½À´Ï´Ù. ÀÌ º¸°í¼­´Â 2025³âÀ» ±âÁØ ¿¬µµ, 2035³âÀ» ¿¹Ãø ¿¬µµ·Î ÇÏ¿© 2025-2035³â±îÁöÀÇ Àü ¼¼°è ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´ÞÀÇ ¸ÅÃâ°ú ¿¹ÃøÀ» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, 2025-2035³â±îÁö Àü ¼¼°è ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´ÞÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR%)À» Á¦½ÃÇÕ´Ï´Ù.

º» º¸°í¼­´Â ±¤¹üÀ§ÇÑ Á¶»ç¸¦ ÅëÇØ ÀÛ¼ºµÇ¾ú½À´Ï´Ù. 1Â÷ Á¶»ç¿¡¼­ ¾Ö³Î¸®½ºÆ®´Â KOL(Key Opinion Leader), ¾÷°è ¸®´õ, ¿ÀÇǴϾð Á¦Á¶¾÷ü¸¦ ´ë»óÀ¸·Î ÀÎÅͺ並 ÁøÇàÇß½À´Ï´Ù. 2Â÷ Á¶»ç¿¡¼­´Â ÁÖ¿ä ±â¾÷ÀÇ Á¦Ç° ÀÚ·á, ¿¬·Ê º¸°í¼­, º¸µµÀÚ·á, °ü·Ã ¹®¼­ µîÀ» Âü°íÇÏ¿© ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ½ÃÀåÀ» Ãß·ÐÇÏ¿´½À´Ï´Ù.

½ÃÀå ÇöȲ
½ÃÀå ±Ô¸ð(2024³â) 978¾ï ´Þ·¯
½ÃÀå ±Ô¸ð(2035³â) 3,159¾ï ´Þ·¯
CAGR 11.3%

º» º¸°í¼­¿¡¼­´Â ¼¼°è ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ½ÃÀå °æÀï ±¸µµ¸¦ Á¶»çÇÏ¿´½À´Ï´Ù. Àü ¼¼°è ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ºÐ¾ß¿¡¼­ »ç¾÷À» Àü°³Çϰí ÀÖ´Â ÁÖ¿ä ±â¾÷µéÀÌ È®ÀεǾúÀ¸¸ç, °¢ ±â¾÷Àº ´Ù¾çÇÑ ¼Ó¼º¿¡ µû¶ó ÇÁ·ÎÆÄÀϸµµÇ¾ú½À´Ï´Ù. ±â¾÷ °³¿ä, À繫 »óÅÂ, ÃÖ±Ù °³¹ß, SWOT´Â ÀÌ º¸°í¼­¿¡¼­ ÇÁ·ÎÆÄÀϸµ µÈ ¼¼°è ³ª³ë ±â¼úÀ» ÅëÇÑ ¾à¹° Àü´Þ ±â¾÷ÀÇ ¼Ó¼ºÀÔ´Ï´Ù.

¼¼°è ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ º¸°í¼­°¡ ´äÇÏ´Â ÁÖ¿ä Áú¹®µé

  • ¿¹Ãø ±â°£ µ¿¾È ¸ðµç Áö¿ª¿¡¼­ ¾ÆÆç·¹½Ã½ºÀÇ ¸ÅÃâ/¼öÀÍÀº?
  • Àü ¼¼°è ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ½ÃÀå¿¡¼­ ºñÁî´Ï½º ±âȸ´Â?
  • ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎ, ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ, ±âȸ, À§Çù ¿äÀÎÀº ¹«¾ùÀΰ¡?
  • ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ CAGR·Î ¼ºÀåÇÒ Áö¿ª ½ÃÀåÀº ¾îµðÀΰ¡?
  • 2035³â ¼¼°è¿¡¼­ °¡Àå ³ôÀº ¼öÀÍÀ» âÃâÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ºÐ¾ß´Â?
  • ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ºÎ¹®Àº?
  • ¼¼°è ½ÃÀå¿¡¼­ »ç¾÷À» Àü°³ÇÏ´Â °¢ ±â¾÷ ½ÃÀå ÁöÀ§´Â?

³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ - Á¶»ç ¸ñÀû ¹× Á¶»ç ¹æ¹ý

³ª³ë ±â¼úÀ» ÅëÇÑ ¾à¹° Àü´Þ ¼¼°è ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ º¸°í¼­´Â °³¿ä·Î ½ÃÀÛÇÏ¿© ¿¬±¸ ¹üÀ§¿Í ¸ñÀûÀ» ¼³¸íÇÕ´Ï´Ù. º» º¸°í¼­¿¡¼­´Â º» Á¶»çÀÇ ¸ñÀû, ½ÃÀå¿¡¼­ Ȱµ¿ÇÏ´Â ÁÖ¿ä º¥´õ ¹× À¯Åë¾÷ü, Á¦Ç° ½ÂÀΰú °ü·ÃµÈ ±ÔÁ¦ ½Ã³ª¸®¿À¿¡ ´ëÇØ ÀÚ¼¼È÷ ¼³¸íÇÕ´Ï´Ù.

º» º¸°í¼­´Â °¡µ¶¼ºÀ» °í·ÁÇÏ¿© °¢ ¼½¼ÇÀ» À庰·Î ³ª´©¾î ·¹À̾ƿôÀ» ±¸¼ºÇÏ¿´½À´Ï´Ù. º» º¸°í¼­´Â ±×·¡ÇÁ¿Í Ç¥¸¦ ÀûÀýÈ÷ ¹èÄ¡ÇÑ Á¾ÇÕÀûÀÎ ÀÚ·á·Î ±¸¼ºµÇ¾î ÀÖ½À´Ï´Ù. ÁÖ¿ä ºÎ¹®ÀÇ ºÐ¼®°ú ¿¹ÃøÄ¡¸¦ µµ½ÄÈ­ÇÏ¿© µ¶ÀÚ¿¡°Ô ½Ã°¢ÀûÀ¸·Î ¾îÇÊÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °ú°Å¿Í ¿¹Ãø ±â°£ ¸»ÀÇ ÁÖ¿ä ºÎ¹®º° ½ÃÀå Á¡À¯À²À» ºñ±³ÇÒ ¼ö ÀÖ½À´Ï´Ù.

º» º¸°í¼­¿¡¼­´Â Á¦Ç° À¯Çü, Åõ¿© °æ·Î, Áö¿ª µîÀÇ °üÁ¡¿¡¼­ Àü ¼¼°è ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´ÞÀ» ºÐ¼®ÇÕ´Ï´Ù. °¢ ±âÁØÀÇ ÁÖ¿ä ºÎ¹®À» »ó¼¼ÇÏ°Ô Á¶»çÇϰí, 2035³â ¸» ±âÁØ °¢ ºÎ¹® ½ÃÀå Á¡À¯À²À» Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±ÍÁßÇÑ ÅëÂû·ÂÀ» ÅëÇØ ½ÃÀå ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è ³ª³ë±â¼ú ±â¹Ý ¾à¹° Àü´Þ ½ÃÀå¿¡ ´ëÇÑ ÅõÀÚ¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ºñÁî´Ï½º ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå ÀüÁ¦Á¶°Ç°ú Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à : ¼¼°è ½ÃÀå

Á¦4Àå ½ÃÀå °³¿ä

  • ¼­·Ð
  • °³¿ä
  • ½ÃÀå ¿ªÇÐ
  • ¼¼°èÀÇ ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ½ÃÀå ºÐ¼®°ú ¿¹Ãø(2020-2035³â)

Á¦5Àå ÁÖ¿ä ÀλçÀÌÆ®

  • ÁÖ¿ä ¾÷°è À̺¥Æ®
  • ÁÖ¿ä ±¹°¡, Áö¿ªº° ¿ªÇÐ
  • °ø±Þ¸Á ºÐ¼®
  • ±â¼úÀû Áøº¸
  • ÁÖ¿ä ±¹°¡, Áö¿ªº° ±ÔÁ¦ ½Ã³ª¸®¿À
  • ½ÃÀå ÁøÃâ Àü·«
  • ÁÖ¿ä Á¦Ç°/ºê·£µå ºÐ¼®
  • PorterÀÇ Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
  • °æÀïÀÌ Á¦°øÇÏ´Â Á¦Ç° º¥Ä¡¸¶Å·

Á¦6Àå ¼¼°è ½ÃÀå ºÐ¼®°ú ¿¹Ãø : Á¦Ç° À¯Çüº°

  • ¼­·Ð ¹× Á¤ÀÇ
  • ÁÖ¿ä ºÐ¼® °á°ú/ÁøÀü
  • ½ÃÀå ¿¹Ãø(±Ý¾× ±âÁØ) : Á¦Ç° À¯Çüº°(2020-2035³â)
    • ³ª³ëÀÔÀÚ
    • ¸®Æ÷¼Ø
    • ¹Ì¼¿
    • ³ª³ë Çöʾ×
    • µ§µå¸®¸Ó
    • ³ª³ëÆ©ºê
    • ±âŸ
  • ½ÃÀåÀÇ ¸Å·Â : Á¦Ç° À¯Çüº°

Á¦7Àå ¼¼°è ½ÃÀå ºÐ¼®°ú ¿¹Ãø : Åõ¿© °æ·Îº°

  • ¼­·Ð ¹× Á¤ÀÇ
  • ÁÖ¿ä ºÐ¼® °á°ú/ÁøÀü
  • ½ÃÀå ¿¹Ãø(±Ý¾× ±âÁØ) : Åõ¿© °æ·Îº°(2020-2035³â)
    • °æ±¸
    • ºñ°æ±¸
    • ±¹¼Ò
    • ±âŸ
  • ½ÃÀåÀÇ ¸Å·Â : Åõ¿© °æ·Îº°

Á¦8Àå ¼¼°è ½ÃÀå ºÐ¼®°ú ¿¹Ãø : ¿ëµµº°

  • ¼­·Ð ¹× Á¤ÀÇ
  • ÁÖ¿ä ºÐ¼® °á°ú/ÁøÀü
  • ½ÃÀå ¿¹Ãø(±Ý¾× ±âÁØ) : ¿ëµµº°(2020-2035³â)
    • Á¾¾ç
    • ½Å°æÁúȯ
    • ½ÉÇ÷°üÁúȯ
    • °¨¿°Áõ
    • È£Èí±âÁúȯ
    • ÀÚ°¡¸é¿ªÁúȯ
    • ±âŸ(¾È°ú µî)
  • ½ÃÀåÀÇ ¸Å·Â : ¿ëµµº°

Á¦9Àå ¼¼°è ½ÃÀå ºÐ¼®°ú ¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°

  • ¼­·Ð ¹× Á¤ÀÇ
  • ÁÖ¿ä ºÐ¼® °á°ú/ÁøÀü
  • ½ÃÀå ¿¹Ãø(±Ý¾× ±âÁØ) : ÃÖÁ¾»ç¿ëÀÚº°(2020-2035³â)
    • º´¿ø ¹× Áø·á¼Ò
    • ¹ÙÀÌ¿ÀÀǾàǰ ±â¾÷
    • ±âŸ
  • ½ÃÀåÀÇ ¸Å·Â : ÃÖÁ¾»ç¿ëÀÚº°

Á¦10Àå ¼¼°è ½ÃÀå ºÐ¼®°ú ¿¹Ãø : Áö¿ªº°

  • ÁÖ¿ä ºÐ¼® °á°ú
  • ½ÃÀå ¿¹Ãø(±Ý¾× ±âÁØ) : : Áö¿ªº°
    • ºÏ¹Ì
    • À¯·´
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¶óƾ¾Æ¸Þ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
  • ½ÃÀåÀÇ ¸Å·Â : Áö¿ªº°

Á¦11Àå ºÏ¹Ì ½ÃÀå ºÐ¼®°ú ¿¹Ãø

  • ¹Ì±¹
  • ij³ª´Ù

Á¦12Àå À¯·´ ½ÃÀå ºÐ¼®°ú ¿¹Ãø

  • µ¶ÀÏ
  • ¿µ±¹
  • ÇÁ¶û½º
  • ÀÌÅ»¸®¾Æ
  • ½ºÆäÀÎ
  • ½ºÀ§½º
  • ³×´ú¶õµå
  • ±âŸ À¯·´

Á¦13Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå ºÐ¼®°ú ¿¹Ãø

  • Áß±¹
  • Àεµ
  • ÀϺ»
  • Çѱ¹
  • È£ÁÖ ¹× ´ºÁú·£µå
  • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç

Á¦14Àå ¶óÆ¾¾Æ¸Þ¸®Ä« ½ÃÀå ºÐ¼®°ú ¿¹Ãø

  • ºê¶óÁú
  • ¸ß½ÃÄÚ
  • ¾Æ¸£ÇîÆ¼³ª
  • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«

Á¦15Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ½ÃÀå ºÐ¼®°ú ¿¹Ãø

  • GCC ±¹°¡
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦16Àå °æÀï ±¸µµ

  • ½ÃÀå ±â¾÷ - °æÀï ¸ÅÆ®¸¯½º(±â¾÷ Tierº°, ±Ô¸ðº°)
  • ½ÃÀå Á¡À¯À² ºÐ¼® ±â¾÷º°(2024³â)
  • ±â¾÷ °³¿ä
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Johnson & Johnson
    • Novartis AG
    • Roche Holding AG
    • AbbVie Inc.
    • Sanofi S.A.
    • Amgen Inc.
    • Celgene Corporation
    • Gilead Sciences, Inc.
LSH 25.08.19

Nanotechnology Drug Delivery - Scope of Report

TMR's report on the global Nanotechnology Drug Delivery studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2025 to 2035. The report provides revenue of the global Nanotechnology Drug Delivery for the period 2025 to 2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Nanotechnology Drug Delivery from 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the two-wheeler navigation display market.

Market Snapshot
Market Value in 2024US$ 97.8 Bn
Market Value in 2035US$ 315.9 Bn
CAGR11.3%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global two-wheeler navigation display market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global two-wheeler navigation display market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global two-wheeler navigation display market.

The report delves into the competitive landscape of the global two-wheeler navigation display market. Key players operating in the global Nanotechnology Drug Delivery have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Nanotechnology Drug Delivery profiled in this report.

Key Questions Answered in Global Nanotechnology Drug Delivery Report:

  • What is the sales/revenue generated by apheresis across all regions during the forecast period?
  • What are the opportunities in the global two-wheeler navigation display market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2035?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Nanotechnology Drug Delivery - Research Objectives and Research Approach

The comprehensive report on the global Nanotechnology Drug Delivery begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Nanotechnology Drug Delivery in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2035 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global two-wheeler navigation display market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Nanotechnology Drug Delivery Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Nanotechnology Drug Delivery Market Analysis and Forecasts, 2020 to 2035
    • 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

  • 5.1. Key Industry Events
  • 5.2. Epidemiology by Key Countries/Regions
  • 5.3. Supply Chain Analysis
  • 5.4. Technological advancements
  • 5.5. Regulatory Scenario by Key Countries/Regions
  • 5.6. Go to Market Strategy
  • 5.7. Key Product/Brand Analysis
  • 5.8. Porter's Five Forces Analysis
  • 5.9. PESTLE Analysis
  • 5.10. Benchmarking of Products offered by Competitors

6. Global Nanotechnology Drug Delivery Market Analysis and Forecasts, By Product Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast By Product Type, 2020 to 2035
    • 6.3.1. Nanoparticles
    • 6.3.2. Liposomes
    • 6.3.3. Micelles
    • 6.3.4. Nanosuspensions
    • 6.3.5. Dendrimers
    • 6.3.6. Nanotubes
    • 6.3.7. Others
  • 6.4. Market Attractiveness By Product Type

7. Global Nanotechnology Drug Delivery Market Analysis and Forecasts, By Route of Administration

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast By Route of Administration, 2020 to 2035
    • 7.3.1. Oral
    • 7.3.2. Parenteral
    • 7.3.3. Topical
    • 7.3.4. Others
  • 7.4. Market Attractiveness By Route of Administration

8. Global Nanotechnology Drug Delivery Market Analysis and Forecasts, By Application

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast By Application, 2020 to 2035
    • 8.3.1. Oncology
    • 8.3.2. Neurology
    • 8.3.3. Cardiovascular Diseases
    • 8.3.4. Infectious Diseases
    • 8.3.5. Respiratory Diseases
    • 8.3.6. Autoimmune Diseases
    • 8.3.7. Others (Ophthalmology, etc.)
  • 8.4. Market Attractiveness By Application

9. Global Nanotechnology Drug Delivery Market Analysis and Forecasts, By End-user

  • 9.1. Introduction & Definition
  • 9.2. Key Findings / Developments
  • 9.3. Market Value Forecast By End-user, 2020 to 2035
    • 9.3.1. Hospitals and Clinics
    • 9.3.2. Biopharmaceutical Companies
    • 9.3.3. Others
  • 9.4. Market Attractiveness By End-user

10. Global Nanotechnology Drug Delivery Market Analysis and Forecasts, By Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast By Region
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness By Region

11. North America Nanotechnology Drug Delivery Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast By Product Type, 2020 to 2035
    • 11.2.1. Nanoparticles
    • 11.2.2. Liposomes
    • 11.2.3. Micelles
    • 11.2.4. Nanosuspensions
    • 11.2.5. Dendrimers
    • 11.2.6. Nanotubes
    • 11.2.7. Others
  • 11.3. Market Value Forecast By Route of Administration, 2020 to 2035
    • 11.3.1. Oral
    • 11.3.2. Parenteral
    • 11.3.3. Topical
    • 11.3.4. Others
  • 11.4. Market Value Forecast By Application, 2020 to 2035
    • 11.4.1. Oncology
    • 11.4.2. Neurology
    • 11.4.3. Cardiovascular Diseases
    • 11.4.4. Infectious Diseases
    • 11.4.5. Respiratory Diseases
    • 11.4.6. Autoimmune Diseases
    • 11.4.7. Others (Ophthalmology, etc.)
  • 11.5. Market Value Forecast By End-user, 2020 to 2035
    • 11.5.1. Hospitals and Clinics
    • 11.5.2. Biopharmaceutical Companies
    • 11.5.3. Others
  • 11.6. Market Value Forecast By Country, 2020 to 2035
    • 11.6.1. U.S.
    • 11.6.2. Canada
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Product Type
    • 11.7.2. By Route of Administration
    • 11.7.3. By Application
    • 11.7.4. By End-user
    • 11.7.5. By Country

12. Europe Nanotechnology Drug Delivery Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast By Product Type, 2020 to 2035
    • 12.2.1. Nanoparticles
    • 12.2.2. Liposomes
    • 12.2.3. Micelles
    • 12.2.4. Nanosuspensions
    • 12.2.5. Dendrimers
    • 12.2.6. Nanotubes
    • 12.2.7. Others
  • 12.3. Market Value Forecast By Route of Administration, 2020 to 2035
    • 12.3.1. Oral
    • 12.3.2. Parenteral
    • 12.3.3. Topical
    • 12.3.4. Others
  • 12.4. Market Value Forecast By Application, 2020 to 2035
    • 12.4.1. Oncology
    • 12.4.2. Neurology
    • 12.4.3. Cardiovascular Diseases
    • 12.4.4. Infectious Diseases
    • 12.4.5. Respiratory Diseases
    • 12.4.6. Autoimmune Diseases
    • 12.4.7. Others (Ophthalmology, etc.)
  • 12.5. Market Value Forecast By End-user, 2020 to 2035
    • 12.5.1. Hospitals and Clinics
    • 12.5.2. Biopharmaceutical Companies
    • 12.5.3. Others
  • 12.6. Market Value Forecast By Country/Sub Region, 2020 to 2035
    • 12.6.1. Germany
    • 12.6.2. U.K.
    • 12.6.3. France
    • 12.6.4. Italy
    • 12.6.5. Spain
    • 12.6.6. Switzerland
    • 12.6.7. The Netherlands
    • 12.6.8. Rest of Europe
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Product Type
    • 12.7.2. By Route of Administration
    • 12.7.3. By Application
    • 12.7.4. By End-user
    • 12.7.5. By Country/Sub Region

13. Asia Pacific Nanotechnology Drug Delivery Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast By Product Type, 2020 to 2035
    • 13.2.1. Nanoparticles
    • 13.2.2. Liposomes
    • 13.2.3. Micelles
    • 13.2.4. Nanosuspensions
    • 13.2.5. Dendrimers
    • 13.2.6. Nanotubes
    • 13.2.7. Others
  • 13.3. Market Value Forecast By Route of Administration, 2020 to 2035
    • 13.3.1. Oral
    • 13.3.2. Parenteral
    • 13.3.3. Topical
    • 13.3.4. Others
  • 13.4. Market Value Forecast By Application, 2020 to 2035
    • 13.4.1. Oncology
    • 13.4.2. Neurology
    • 13.4.3. Cardiovascular Diseases
    • 13.4.4. Infectious Diseases
    • 13.4.5. Respiratory Diseases
    • 13.4.6. Autoimmune Diseases
    • 13.4.7. Others (Ophthalmology, etc.)
  • 13.5. Market Value Forecast By End-user, 2020 to 2035
    • 13.5.1. Hospitals and Clinics
    • 13.5.2. Biopharmaceutical Companies
    • 13.5.3. Others
  • 13.6. Market Value Forecast By Country/Sub Region, 2020 to 2035
    • 13.6.1. China
    • 13.6.2. India
    • 13.6.3. Japan
    • 13.6.4. South Korea
    • 13.6.5. Australia & New Zealand
    • 13.6.6. Rest of Asia Pacific
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Product Type
    • 13.7.2. By Route of Administration
    • 13.7.3. By Application
    • 13.7.4. By End-user
    • 13.7.5. By Country/Sub Region

14. Latin America Nanotechnology Drug Delivery Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast By Product Type, 2020 to 2035
    • 14.2.1. Nanoparticles
    • 14.2.2. Liposomes
    • 14.2.3. Micelles
    • 14.2.4. Nanosuspensions
    • 14.2.5. Dendrimers
    • 14.2.6. Nanotubes
    • 14.2.7. Others
  • 14.3. Market Value Forecast By Route of Administration, 2020 to 2035
    • 14.3.1. Oral
    • 14.3.2. Parenteral
    • 14.3.3. Topical
    • 14.3.4. Others
  • 14.4. Market Value Forecast By Application, 2020 to 2035
    • 14.4.1. Oncology
    • 14.4.2. Neurology
    • 14.4.3. Cardiovascular Diseases
    • 14.4.4. Infectious Diseases
    • 14.4.5. Respiratory Diseases
    • 14.4.6. Autoimmune Diseases
    • 14.4.7. Others (Ophthalmology, etc.)
  • 14.5. Market Value Forecast By End-user, 2020 to 2035
    • 14.5.1. Hospitals and Clinics
    • 14.5.2. Biopharmaceutical Companies
    • 14.5.3. Others
  • 14.6. Market Value Forecast By Country/Sub Region, 2020 to 2035
    • 14.6.1. Brazil
    • 14.6.2. Mexico
    • 14.6.3. Argentina
    • 14.6.4. Rest of Latin America
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Product Type
    • 14.7.2. By Route of Administration
    • 14.7.3. By Application
    • 14.7.4. By End-user
    • 14.7.5. By Country/Sub Region

15. Middle East & Africa Nanotechnology Drug Delivery Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast By Product Type, 2020 to 2035
    • 15.2.1. Nanoparticles
    • 15.2.2. Liposomes
    • 15.2.3. Micelles
    • 15.2.4. Nanosuspensions
    • 15.2.5. Dendrimers
    • 15.2.6. Nanotubes
    • 15.2.7. Others
  • 15.3. Market Value Forecast By Route of Administration, 2020 to 2035
    • 15.3.1. Oral
    • 15.3.2. Parenteral
    • 15.3.3. Topical
    • 15.3.4. Others
  • 15.4. Market Value Forecast By Application, 2020 to 2035
    • 15.4.1. Oncology
    • 15.4.2. Neurology
    • 15.4.3. Cardiovascular Diseases
    • 15.4.4. Infectious Diseases
    • 15.4.5. Respiratory Diseases
    • 15.4.6. Autoimmune Diseases
    • 15.4.7. Others (Ophthalmology, etc.)
  • 15.5. Market Value Forecast By End-user, 2020 to 2035
    • 15.5.1. Hospitals and Clinics
    • 15.5.2. Biopharmaceutical Companies
    • 15.5.3. Others
  • 15.6. Market Value Forecast By Country/Sub Region, 2020 to 2035
    • 15.6.1. GCC Countries
    • 15.6.2. South Africa
    • 15.6.3. Rest of Middle East & Africa
  • 15.7. Market Attractiveness Analysis
    • 15.7.1. By Product Type
    • 15.7.2. By Route of Administration
    • 15.7.3. By Application
    • 15.7.4. By End-user
    • 15.7.5. By Country/Sub Region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 16.2. Market Share Analysis By Company (2024)
  • 16.3. Company Profiles
    • 16.3.1. Merck & Co., Inc.
      • 16.3.1.1. Company Overview
      • 16.3.1.2. Financial Overview
      • 16.3.1.3. Financial Overview
      • 16.3.1.4. Business Strategies
      • 16.3.1.5. Recent Developments
    • 16.3.2. Pfizer Inc.
      • 16.3.2.1. Company Overview
      • 16.3.2.2. Financial Overview
      • 16.3.2.3. Financial Overview
      • 16.3.2.4. Business Strategies
      • 16.3.2.5. Recent Developments
    • 16.3.3. Johnson & Johnson
      • 16.3.3.1. Company Overview
      • 16.3.3.2. Financial Overview
      • 16.3.3.3. Financial Overview
      • 16.3.3.4. Business Strategies
      • 16.3.3.5. Recent Developments
    • 16.3.4. Novartis AG
      • 16.3.4.1. Company Overview
      • 16.3.4.2. Financial Overview
      • 16.3.4.3. Financial Overview
      • 16.3.4.4. Business Strategies
      • 16.3.4.5. Recent Developments
    • 16.3.5. Roche Holding AG
      • 16.3.5.1. Company Overview
      • 16.3.5.2. Financial Overview
      • 16.3.5.3. Financial Overview
      • 16.3.5.4. Business Strategies
      • 16.3.5.5. Recent Developments
    • 16.3.6. AbbVie Inc.
      • 16.3.6.1. Company Overview
      • 16.3.6.2. Financial Overview
      • 16.3.6.3. Financial Overview
      • 16.3.6.4. Business Strategies
      • 16.3.6.5. Recent Developments
    • 16.3.7. Sanofi S.A.
      • 16.3.7.1. Company Overview
      • 16.3.7.2. Financial Overview
      • 16.3.7.3. Financial Overview
      • 16.3.7.4. Business Strategies
      • 16.3.7.5. Recent Developments
    • 16.3.8. Amgen Inc.
      • 16.3.8.1. Company Overview
      • 16.3.8.2. Financial Overview
      • 16.3.8.3. Financial Overview
      • 16.3.8.4. Business Strategies
      • 16.3.8.5. Recent Developments
    • 16.3.9. Celgene Corporation
      • 16.3.9.1. Company Overview
      • 16.3.9.2. Financial Overview
      • 16.3.9.3. Financial Overview
      • 16.3.9.4. Business Strategies
      • 16.3.9.5. Recent Developments
    • 16.3.10. Gilead Sciences, Inc.
      • 16.3.10.1. Company Overview
      • 16.3.10.2. Financial Overview
      • 16.3.10.3. Financial Overview
      • 16.3.10.4. Business Strategies
      • 16.3.10.5. Recent Developments
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦